#Hypolipidemic drugs Market Share | Explore Tumblr Posts and Blogs

precisemarketreportsandinsights · 7 years

Text

Hypolipidemic drugs Market Share And Analysis Report 2017 By Radiant Insights,Inc

This report splits Hypolipidemic drugs by Product Cholic acid regulator, by Product HMG-CoA reductase inhibitors, by Product Adenylate cyclase inhibitors, by Product Nicotinic acid drugs, by Product Others. This shares the history data information from 2012 to 2016, and forecast from 2017 to 2022.

And this report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Hypolipidemic drugs industry.

Browse Full Research Report with TOC on https://www.radiantinsights.com/research/global-hypolipidemic-drugs-detailed-analysis-report-2017-2022

This report focus Global market, it covers details players regions product type and other details as following:

Major Companies

• ABBOTT LABORATORIES LIMITED

• Apotex Fermentation Inc.

• BIOCON LIMITED IN Bangalore

• Cadila Healthcare Limited

• Chunghwa Chem Syn& Biotech Co., Ltd

• CONCORD BIOTECH LIMITED Ahmedabad

• Croda Europe Limited Leek

• DAIICHI SANKYO CO., LTD. JP

• Dr. Reddy's Laboratories Ltd

• DSM Sinochem Pharma India

• HIKAL LIMITED Bangalore

• IPCA Laboratories Limited

• Lek Pharmaceuticals d.d.

• LUPIN LIMITED

• Merck Sharp & Dohme B.V.

• Moehs Iberica S.L. ES

• MYLAN LABORATORIES LIMITED

• Nexchem Pharmaceutical Co., Ltd. CN

• OLON S.P.A. IT Rodano

• Pfizer Inc.

• Recordati S.p.A. IT Milano

• SUN PHARMACEUTICAL LIMITED Mumbai

• TEVA PHARMACEUTICAL Petach Tikva

• Zhejiang Jiangbei Pharma Co. Ltd CN

Request A Sample Copy of This Report at: https://www.radiantinsights.com/research/global-hypolipidemic-drugs-detailed-analysis-report-2017-2022/request-sample

Main Regions

• United States

• Europe

• Germany

• United Kingdom

• France

• Italy

• Spain

• Russia

• Netherland

• Poland

• Others

• China

• Japan

• India

• Southeast Asia

• Others

Main Product Type

Hypolipidemic drugs Market, by Product Cholic acid regulator

• ChoIestyramine

• CoIestipol

• Divistyramine

Hypolipidemic drugs Market, by Product HMG-CoA reductase inhibitors

• Simvastatin

• Lovastatin

• Pravastatin

• Atorvastatin

• Fluvastatin

Hypolipidemic drugs Market, by Product Adenylate cyclase inhibitors

• Clofibrate

• Fenofibrate

• Lifibrate

• Etofylline Clofibrate

• Gfibrozil

• Bezafibrate

• Simfibrate

Hypolipidemic drugs Market, by Product Nicotinic acid drugs

• Nicotinic Acid

• Lnositol Hexanicotinate

• Acipimox

Hypolipidemic drugs Market, by Product Others

• Omega-3

• Pantethine

• Probucol

• Elastase

Main Applications

• Hospital

• Pharmacy

• Clinic

• Cardiovasology

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Media Contact:

Michelle Thoras

201 Spear Street 1100,

Suite 3036, San Francisco,

CA 94105, United States

Tel: 1-415-349-0054

Toll Free: 1-888-928-9744

Mail: [email protected]

#Hypolipidemic drugs Market Share #Hypolipidemic drugs Market Analysis #Hypolipidemic drugs Market Growth #Hypolipidemic drugs Market Size

0 notes

viz-release-blog · 5 years

Text

Research and Markets: Research Report on Chinas Hypolipidemic Drug Market, 2012-2013

New Post has been published on https://vizrelease.com/press-release/1364967/

Research and Markets: Research Report on Chinas Hypolipidemic Drug Market, 2012-2013

According to surveys, the overall morbidity rate of dyslipidemia groups aged 18 and above is over 20% in China, and total patients are over 200 million nationwide. Blood lipid levels and morbidity rate of dyslipidemia of Chinese people are still lower than that in most developed countries. However, with the development of China’s economy, improvement in people’s living standards and changes in lifestyle, the morbidity rate of dyslipidemia gradually rises. Meanwhile, diabetes and metabolic syndrome closely related to dyslipidemia are also common in China.

According to market research, the market size of China’s hypolipidemic drugs exceeded CNY 12 billion in 2011, with an annual growth rate of over 15 %.

At present, blood lipid controlling drugs in the Chinese market are mainly divided into five categories: statins, fibrates, nicotinic acids, resins and cholesterol absorption inhibitors, also including some other drugs. Statins and fibrates occupy the largest market share in the Chinese market, and applications of other drugs are relatively a few. In terms of the market share of major varieties, the total market share of the top 5 hypolipidemic drug varieties in China was over 80% in 2009. Among them, the top 4 products all were statins (respectively: Atorvastatin, Simvastatin, Pravastatin and Fluvastatin), which occupied nearly 80% of the market share. In 2011, the market share of the top 5 varieties in China’s hypolipidemic market was 82.64%. Among them, the top 4 products were still statins (respectively: Atorvastatin, Simvastatin, Pravastatin and Fluvastatin), which accounted for 78% of the share. It is obvious that statin products are main forces in hyperlipidemia treatment drug market of China. Statins are always in leading positions in China’s hypolipidemic drug market. Because of excellent effects, little side effects and other multiple effects including lowering overall mortality rate, statin drugs are major drugs in the joint lipid-lowering program, thus occupying a most advantageous position clinically.

The overall performance of China’s hypolipidemic drugs in the drug market is better than that of the entire drug and cardiovascular system drug markets, showing a strong growth momentum. The expansion speed of hypolipidemic drug market is evidently higher than that of the cardiovascular drug market, and the proportion in cardiovascular system drugs gradually rises.

More following information can be acquired through this report:

– Status Quo of China’s Hypolipidemic Drug Market

– Status Quo of China’s Statin Drug Market

– Market Size of Major Varieties of China’s Hypolipidemic Drugs

– Competition in China’s Hypolipidemic Drug Market

– Market Prices of Major Hypolipidemic Drugs in China

– Prediction on Development of China’s Hypolipidemic Drugs

Following people are recommended to buy this report:

– Pharmaceutical Enterprises

– Pharmaceutical Trade Enterprises

– Hospitals

– Investors/Research Institutions Focusing on China’s Pharmaceutical industry

Chapter ONE: Clinical Application Status and Classification of Hypolipidemic Drugs

Chapter TWO: Analysis on Market Size of China’s Hypolipidemic Drugs, 2011-2012

Chapter THREE: Competition in China’s Hypolipidemic Drug Market, 2011-2012

Chapter FOUR: Analysis on Market Competition in Major Varieties of China’s Hypolipidemic Drugs

Chapter FIVE: RandD of Hypolipidemic Drugs, 2011-2012

Chapter SIX: Prediction on China’s Hypolipidemic Drug Market, 2013-2017

0 notes

srikanthgtbrc-blog · 5 years

Text

Global Hypolipidemics Market Overview And Top Key Players In 2019

The Business Research Company’s Hypolipidemics Global Market Report 2019 covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. Ratios of market size and growth to related markets, GDP proportions, and expenditure per capita for the market is detailed in the report. Data and analysis throughout the report is sourced using end notes.

Browse Hypolipidemics Global Market Report 2019

https://www.thebusinessresearchcompany.com/report/hypolipidemics-global-market-report

The hypolipidemics market is a segment of the pharmaceuticals market. The report will answer questions such as where the largest and fastest growing market is, how the market relates to the overall economy, demography and other similar markets, and what forces will shape the market going forward.The hypolipidemic drugs market consists of sales of hypolipidemic drugs and related services. This industry includes establishments that produce hypolipidemic drugs or agents that lower lipid and lipoproteins levels in the blood. These drugs can be used to prevent cardiovascular diseases and atherosclerosis in Hyperlipidemia patients. Some of the major hypolipidemic drugs include fibric acid derivatives, bile acid binding resins, nicotinamides, and cholesterol absorption inhibitors.

Place A Sample Request Of This Report At:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2435&type=smp

List Of Tables

Table 1: Global Historic Market Growth, 2014-2018, $ Billion

Table 2: Global Forecast Market Growth, 2014-2022F, 2025F, 2030F, $ Billion

Table 3: Global Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 4: Global Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 5: Global Hypolipidemic Drugs Market, Split By Region, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 6: Global Hypolipidemic Drugs Market, Split By Country, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 7: Asia-Pacific, Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 8: Asia-Pacific, Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 9: China, Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 10: China, Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

View More Press Releases:

https://www.thebusinessresearchcompany.com/press-release.aspx

About The Business Research Company:

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. The company has specialist consultants in different industries including manufacturing, healthcare, financial services and technology. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information

The Business Research Company

https://www.thebusinessresearchcompany.com

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: [email protected]

#hypolipidemics market

0 notes

theshadowytastemakerstuden-blog1 · 6 years

Text

Global Fatty Liver Disease Drugs Market Competitive Analysis of Top Players in Market

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Fatty Liver Disease Market on the basis of Type (Alcoholic Fatty Liver Disease or ALD), Non Alcoholic Fatty Liver Disease or NAFLD), By Alcoholic Fatty Liver Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By Non Alcoholic Fatty Liver Stages (Non Alcoholic Steatosis, Non Alcoholic Steatohepatitis or NASH), By Alcoholic Liver Disease Drug (Opiod Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor), By Non Alcoholic Fatty Liver Drug (Antioxidants Thiazolidinedione, Biguanides, Lipid Lowering agents, FXR receptor agonist, Elafibranoer), By Region (North America, Europe, Asia Pacific and ROW) and By Country (U.S., Canada , U.K., France, Germany, China, Japan, India, Brazil, South Africa and Saudi Arabia).

Fill the form to get Exclusive Sample at: https://www.researchmoz.us/enquiry.php?type=S&repid=1256620

Over the recent years, the global fatty liver disease incidence has been growing rapidly with increase in prevalence of obesity, type II diabetes along with rising consumption of alcohol. Globally, the growth in the fatty liver disease market is driven by rising awareness among people by government organizations and private companies, heavy investments by pharmaceutical companies for the development of drugs along with launch of drugs for NASH in the forecasted period.

According to Azoth Analytics research report, the report Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) – By ALD Stages (Alcoholic Steatosis ,Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH) analyses the Global Fatty Liver Disease Market, Analysis By Type (Alcoholic Fatty Liver Disease or ALD), Non Alcoholic Fatty Liver Disease or NAFLD), By Alcoholic Fatty Liver Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis or ASH), By Non Alcoholic Fatty Liver Stages (Non Alcoholic Steatosis, Non Alcoholic Steatohepatitis or NASH), By Alcoholic Liver Disease Drug (Opiod Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor) and By Non Alcoholic Fatty Liver Drug (Antioxidants Thiazolidinedione, Biguanides, Lipid Lowering agents, FXR receptor agonist, Elafibranoer). The global market is projected to display a robust growth represented by a CAGR of 22.67% during 2017 2022, chiefly driven by rising prevalence of obesity, diabetes and hypertension, rising clinical trials in Asian countries, heavy investments by government of different countries in their health care sector, rising research in developing the different health care machines and methodology for the detection of alcohol and non-alcohol steatosis at its early stage.

Read Overview of Report @ https://www.researchmoz.us/global-fatty-liver-disease-drugs-market-by-type-ald-nafld-by-stages-of-ald-and-nafld-by-region-by-country-opportunities-and-forecast-2017-2022-by-ald-stages-alcoholic-steatosis-alcoholic-steatohepatitis-by-nafld-stages-steatosis-nash-report.html

The report titled, Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) – By ALD Stages (Alcoholic Steatosis ,Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH) has covered and analysed the potential of Global Fatty Liver Disease Market, NASH and NAFLD markets and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global fatty liver disease market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022) Fatty Liver Disease market Breakdown By NAFLD Stages (2012-2022): (Steatosis , NASH) Breakdown By ALD Stages (2012-2022): (Steatosis, Alcohol Hepatitis) Breakdown by ALD Drugs (2012-2022): (Opioid Antagonist ,Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor) Breakdown By NAFLD Drug (2012-2022): (Antioxidants Thiazolidinedione, Biguanides, Hypolipidemic Agents, FXR receptor agonist, Elafibranoer)

Regional Markets North America, Europe, APAC, ROW (Actual Period: 2012-2016 Forecast Period: 2017-2022) Fatty Liver Disease market Fatty Liver Disease market By Type (ALD, NAFLD) Breakdown by ALD Drugs (2012-2022) Breakdown By NAFLD Drug (2012-2022)

Make An Enquiry@ https://www.researchmoz.us/enquiry.php?type=E&repid=1256620

Country Analysis – UK, Germany, France, India, China, Japan, Brazil, Saudi Arabia, South Africa, U.S. and Canada (Actual Period: 2012-2016, Forecast Period: 2017-2022) Fatty Liver Disease market Fatty Liver Disease market By Type (ALD, NAFLD)

Other Report Highlights Market Dynamics Trends, Drivers, Challenges Policy and Regulation Company Analysis Pfizer, Gilead Sciences ,Astra Zenca, Immuron, Novartis,Takeda, Allergan , Intercept Pharmaceuticals, Conatus

Customization of the Report The report could be customized according to the clients specific research requirements. No additional cost will be required to pay for limited additional research.

About ResearchMoz ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact: ResearchMoz Mr. Nachiket Ghumare, Tel: +1-518-621-2074 USA-Canada Toll Free: 866-997-4948 Website: https://www.researchmoz.us Email: [email protected] Blog: https://researchknowledgeresource.blogspot.com/ Follow us on LinkedIn @ http://bit.ly/1TBmnVG

0 notes

inewswork01 · 7 years

Link

via News Planet

#Latest News

0 notes

thomasmartin16blr-blog · 7 years

Text

Worldwide and Europe Hypolipidemic drugs Market – Analysis and Outlook to 2022 – Reports Monitor

This report presents a comprehensive overview of the Hypolipidemic drugs market in Europe. This shares the history data information from 2012 to 2016, and forecast from 2017 to 2022.

This report provides a detailed analysis of the market, its dynamics, structure, characteristics, main players, growth and demand drivers, etc. As a Detailed Analysis report, it covers all details inside analysis and opinion in Hypolipidemic drugs industry.

This report focus Global and Europe market, it covers details players regions product type and other details as following:

To Browse Complete report visit @ https://www.reportsmonitor.com/global-and-europe-hypolipidemic-drugs-market-analysis-and-outlook-to-2022/ Key Players

ABBOTT LABORATORIES LIMITED Moehs Iberica S.L. ES Apotex Fermentation Inc. MYLAN LABORATORIES LIMITED BIOCON LIMITED IN Bangalore Nexchem Pharmaceutical Co., Ltd. CN Cadila Healthcare Limited OLON S.P.A. IT Rodano Chunghwa Chem Syn& Biotech Co., Ltd Pfizer Inc. CONCORD BIOTECH LIMITED Ahmedabad Recordati S.p.A. IT Milano Croda Europe Limited Leek SUN PHARMACEUTICAL LIMITED Mumbai DAIICHI SANKYO CO., LTD. JP TEVA PHARMACEUTICAL Petach Tikva Dr. Reddy�s Laboratories Ltd Zhejiang Jiangbei Pharma Co. Ltd CN DSM Sinochem Pharma India HIKAL LIMITED Bangalore IPCA Laboratories Limited Lek Pharmaceuticals d.d. LUPIN LIMITED Merck Sharp & Dohme B.V.

Key Regions Europe Germany United Kingdom France Italy Spain Russia Netherland Poland Others United States China Japan India Others

To Get Request Sample report visit @ https://www.reportsmonitor.com/request-sample/?post=259951

Key Product Type

by Product Cholic acid regulator ChoIestyramine, CoIestipol, Divistyramine

by Product HMG-CoA reductase inhibitors Simvastatin, Lovastatin, Pravastatin, Atorvastatin, Fluvastatin

by Product Adenylate cyclase inhibitors Clofibrate, Fenofibrate, Lifibrate, Etofylline Clofibrate, Gfibrozil

by Product Nicotinic acid drugs Nicotinic Acid, Lnositol Hexanicotinate, Acipimox

by Product Others Omega-3, Pantethine, Probucol, Elastase

Key Applications

Hospital Pharmacy Clinic Cardiovasology

About Us

Reports Monitor (ReportsMonitor.com) is a platform for companies looking to meet their market research and business intelligence requirements. Our aim is to change the dynamics of the Market Research industry by providing quality intelligence backed by data. Your requirement for market forecasting is fulfilled by our exclusive quantitative and analytics driven intelligence. We have a vast collection of reports, covering maximum industries worldwide. Our process is meticulously planned and executed in order to use maximum resources and explore the market for getting genuine insights. The prime focus is to get reliable data, Decision makers can now rely on our distinct data gathering methods to get factual market forecasting and detailed analysis.

Jay Matthews

Direct: +1 513 549-5911

Email: [email protected]

Website: http://www.reportsmonitor.com

0 notes